Conor is barred from selling CoStar paclitaxel stents in The Netherlands.
Boston Scientific and Angiotech Pharmaceuticals won a patent infringement case against Conor Medsystems in The Netherlands. The District Court in The Hague ruled that Conor’s CoStar™ paclitaxel stent infringed a key claim of the Dutch version of Angiotech’s European paclitaxel stent patent and upheld the validity of that claim.
The Court thus prohibited Conor from selling the infringing CoStar paclitaxel stent in The Netherlands. The Court also ordered Conor to pay damages and/or surrender profits resulting from the infringement.
On Tuesday, January 16, a U.K. court denied Angiotech’s appeal of a ruling that invalidated in Britain one of several patents related to its paclitaxel-eluting stents. The patent, which is part of a worldwide patent portfolio exclusively licensed to Boston Scientific, is still valid and enforceable in all designated European jurisdictions except the U.K.